Lymph node oesophagus cancer
CT0075
n.d.
 Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Oesophagus |
Dr. Moishe Liberman
Adeline Jouquan
514-890-8000 poste 26214
|
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression
FORTITUDE-102
NCT05111626
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Oesophagus
Stomach |
Dr. Mustapha Tehfé
Chantal Gosselin
514-890-8000 poste 24892
|
A Randomized, open-label, multicenter phase 3 trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
STAR-221
NCT05568095
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Oesophagus
Stomach |
Dr. Mustapha Tehfé
Chantal Gosselin
514-890-8000 poste 24892
|
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression
FORTITUDE-101
NCT05052801
Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Oesophagus
Stomach |
Dr. Petr Kavan
Aline Mamo
514-340-8222 poste 5525
|
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression
FORTITUDE-102
NCT05111626
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
Oesophagus
Stomach |
Dr. Maxime Chénard-Poirier
Maryse Gingras
418-691-5781
|
Groupe d'étude en oncologie du Québec